PKP2

Across TCGA pan-cancer cohorts, PKP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PKP2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PKP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PKP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, LIHC, and UCEC are the cancer types where PKP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
LIHC	OS	Median	II,III,IV	0.198	0.715	.012	12	view →
UCEC	DFS	Median	All	0.917	0.620	.029	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	II,III,IV	0.837	0.671	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PKP2–BLCA (OS)

Open the BLCA breakdown →